CING
HEALTHCARECingulate Inc
$5.33+0.35 (+7.03%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CING Today?
No stock-specific AI insight has been generated for CING yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.20$11.89
$5.33
Fundamentals
Market Cap$65M
P/E Ratio—
EPS$-4.44
Dividend Yield—
Dividend / Share—
ROE-4.5%
Profit Margin—
Debt / Equity—
Trading
Volume339K
Avg Volume (10D)—
Shares Outstanding12.3M
CING News
20 articles- Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold ForeverYahoo Finance·Apr 24, 2026
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25Yahoo Finance·Apr 6, 2026
- CING: Laying the Foundation for 1H:27 LaunchYahoo Finance·Mar 20, 2026
- Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsYahoo Finance·Mar 18, 2026
- Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq RulesYahoo Finance·Feb 17, 2026
- EUDA Health Holdings Limited Announces Execution of Securities Purchase AgreementYahoo Finance·Dec 5, 2025
- Cingulate price target lowered to $16 from $17 at Roth CapitalYahoo Finance·Nov 20, 2025
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25Yahoo Finance·Nov 18, 2025
- CING: Third Quarter ResultsYahoo Finance·Nov 17, 2025
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 13, 2025
- Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301Yahoo Finance·Nov 10, 2025
- Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom ControlYahoo Finance·Oct 28, 2025
- Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual MeetingYahoo Finance·Oct 23, 2025
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA DateYahoo Finance·Oct 14, 2025
- Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD TreatmentYahoo Finance·Sep 17, 2025
- CING: NDA SubmittedYahoo Finance·Aug 25, 2025
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25Yahoo Finance·Aug 21, 2025
- Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent HighlightsYahoo Finance·Aug 19, 2025
- Cingulate Provides Management Team UpdateYahoo Finance·Aug 15, 2025
- Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301Yahoo Finance·Aug 6, 2025
All 20 articles loaded
Price Data
Open$5.10
Previous Close$4.98
Day High$5.40
Day Low$5.06
52 Week High$11.89
52 Week Low$3.20
52-Week Range
$3.20$11.89
$5.33
Fundamentals
Market Cap$65M
P/E Ratio—
EPS$-4.44
Dividend Yield—
Dividend / Share—
ROE-4.5%
Profit Margin—
Debt / Equity—
Trading
Volume339K
Avg Volume (10D)—
Shares Outstanding12.3M
About Cingulate Inc
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders. The company is headquartered in Kansas City, Kansas.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—